Travoprost 0.004%/timolol 0.5% fixed combination in patients transitioning from fixed or unfixed bimatoprost 0.03%/timolol 0.5%

Advances in Therapy

Volumn 28, Issue 8, 2011, Pages 661-670

  Scherzer, Maria Luise ^a   Liehneova, Ivana ^b   Negrete, Francisco Jose Mut̃oz ^c   Schnober, Dietmar ^d  

^a Marktplatz 1 ^*  (Germany)

^b MASARYK UNIVERSITY   (Czech Republic)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Facharzt fuer Augenheilkunde (private practice)   (Germany)

Author keywords

Bimatoprost; Fixed combination; Glaucoma; Intraocular pressure; Prostaglandin analog; Timolol; Travoprost

Indexed keywords

BIMATOPROST; BIMATOPROST PLUS TIMOLOL; TIMOLOL; TIMOLOL PLUS TRAVOPROST;

ADULT; AGED; ARTICLE; BLURRED VISION; BURNING SENSATION; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG PREFERENCE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EVENING DOSAGE; EYE BURNING; EYE DISEASE; FEMALE; FOREIGN BODY; GLAUCOMA; HEALTH SURVEY; HUMAN; IATROGENIC DISEASE; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR HYPEREMIA; OPEN ANGLE GLAUCOMA; OPEN STUDY; OUTCOME ASSESSMENT; PIGMENT DISPERSION GLAUCOMA; STINGING; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY;

ADULT; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DRUG COMBINATIONS; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; TIMOLOL;

EID: 82455212737     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0043-z     Document Type: Article

References (14)

1. European Glaucoma Society. Terminology andGuidelines for Glaucoma. 3rd edition. Savona:Editrice Dogma S.r.l.;2008.
2. DuoTrav eye drops solution: Summary ofpatient characteristics. Hemel Hempstead: AlconLaboratories (U.K.) Limited; 2011.
3. Gross RL, Sullivan EK, Wells DT, Mallick S, LandryTA, Bergamini MVW. Pooled results of tworandomized clinical trials comparing the efficacyand safety of travoprost 0.004%/timolol 0.5% infixed combination versus concomitant travoprost0.004% and timolol 0.5%. Clin Ophthalmol.2007;1:317-322.
4. Centofanti M, Oddone F, Gandolfi S., et al.Comparison of travoprost and bimatoprostplus timolol fixed combinations in open-angleglaucoma patients previously treated withlatanoprost plus timolol fixed combination. Am JOphthalmol. 2010;150:575-580.
5. Konstas AGP, Mikropoulos AD, Embeslidis TA,et al. 24-h intraocular pressure control withevening-dosed travoprost/timolol, comparedwith latanoprost/timolol, fixed combinations inexfoliative glaucoma. Eye (Lond). 2010;24:1606-1613.
6. Teus MA, Miglior S, Laganovska G., et al. C-05-25Study Group. Efficacy and safety of travoprost/timolol vs. dorzolamide/timolol in patients withopen-angle glaucoma or ocular hypertension. ClinOphthalmol. 2009;3:629-636.
7. Arend K-O, Raber T. Observational study resultsin glaucoma patients undergoing a regimenreplacement to fixed combination travoprost0.004%/timolol 0.5% in Germany. J OculPharmacol Ther. 2008;24:414-420.
8. Pfeiffer N, Scherzer M-L, Maier H., et al. DuoTrav Med Study Group. Safety and efficacy of changingto the travoprost/timolol maleate fixed combination(DuoTrav) from prior mono- or adjunctive therapy. Clin Ophthalmol. 2010;4:459-466.
9. Rossi GCM, Pasinetti GM, Bracchino M., et al.Switching from concomitant latanoprost 0.005%and timolol 0.5% to a fixed combination oftravoprost 0.004%/timolol 0.5% in patientswith primary open-angle glaucoma and ocular hypertension: A 6-month, multicenter, cohort study. Expert Opin Pharmacother. 2009;10:1705-1711.
10. The AGIS Investigators. The Advanced GlaucomaIntervention Study (AGIS): 7. The relationshipbetween control of intraocular pressure andvisual field deterioration. Am J Ophthalmol.2000;130:429-440.
11. Chauhan BC, Mikelberg FS, Balaszi AG, LeBlancRP, Lesk MR, Trope GE. Canadian Glaucoma StudyGroup. Canadian Glaucoma Study: 2. Risk factorsfor the progression of open-angle glaucoma. ArchOphthalmol. 2008;126:1030-1036.
12. Leske MC, Heijl A, Hussein M, Bengtsson B, HymanL, Komaroff E. Early Manifest Glaucoma TrialGroup. Factors for glaucoma progression and theeffect of treatment: The early manifest glaucomatrial. Arch Ophthalmol. 2003;121:48-56. (Pubitemid 36401765)
13. Holló G. The side effects of the prostaglandinanalogues. Expert Opin Drug Saf. 2007;6:45-52.
14. Bland JM, Altman DG. Regression towards themean. BMJ. 1994;308:1499.